FOLH1 and prostate cancer: PRIMARY study established that a combination of MRI and prostate-specific membrane antigen positron emission tomography reduces false negatives for clinically significant prostate cancer (csPCa) compared with MRI alone hence reducing the number of prostate biopsies required to diagnose cancer prostate (Emmett et al. 2021).